- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02571192
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
April 30, 2019 updated by: Mirum Pharmaceuticals, Inc.
A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects
The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Covance Madison Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age between 18 and 50 years, inclusive, at the time of consent.
- Must be considered healthy. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, thyroid panel (includes T3, T4 and TSH at Screening only), blood chemistry, coagulation and urinalysis
- Must have a body mass index between 18.0-30.0kg/m² inclusive with a body weight >50 kg (110 lbs).
- Ability to swallow all investigational product.
- A minimum of 1 bowel movement per day.
Exclusion Criteria:
- History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gallbladder removal, gastric bypass surgery, ileal resection, any small intestinal resection,or current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.
- Current or relevant history of physical or psychiatric illness.
- Known or suspected intolerance or hypersensitivity to the investigational product, or closely-related compounds, or any of the stated ingredients.
- Significant illness, as judged by the investigator, within 2 weeks of the dose of investigational product.
- Known history of alcohol or other substance abuse within the last year.
- Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to the dose of investigational product.
Within 30 days prior to the dose of investigational product:
- Have used an investigational product (if elimination half-life is <6 days, otherwise 5 half-lives).
- Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
- Have had any substantial changes in eating habits, as assessed by the investigator.
- Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure >89mmHg or <49mmHg.
- Twelve-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject's eligibility.
- A positive screen for drugs of abuse at Screening or a positive screen for alcohol or drugs of abuse at Check-in (Day -1).
- Male subjects who consume more than 21 units of alcohol per week or 3 units of alcohol per day.
- A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen, or hepatitis C virus antibody screen.
- Use of tobacco in any form
- Routine consumption of more than 2 units of caffeine per day
- Current use of any medication including over-the-counter, herbal, or homeopathic preparations
- An inability to follow a standardized diet and meal schedule or inability to fast
- Have participated in a [14C]-study within the last 6 months prior to the dose of investigational product.
- Exposure to clinically significant radiation within 12 months prior to the dose of investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Drug
single oral dose radiolabelled 50mg of SHP626
|
single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.
Time Frame: Day 1 to day 10
|
Day 1 to day 10
|
Total radioactivity (RAD) in whole blood and plasma
Time Frame: Day 1 to day 10
|
Day 1 to day 10
|
To determine the total RAD in urine and feces.
Time Frame: Day 1 to day 10
|
Day 1 to day 10
|
Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)
Time Frame: Day 1 to day 10
|
Day 1 to day 10
|
Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentration
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Area under the plasma concentration curve (AUC0-∞ ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentration
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RAD
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbed
Time Frame: Day 1-10
|
Day 1-10
|
Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbed
Time Frame: Day 1-10
|
Day 1-10
|
Cumulative amount (Aef )of RAD recovered in stool over the dosing interval
Time Frame: Day 1-10
|
Day 1-10
|
Excreted Percent of RAD recovered in stool over the dosing interval
Time Frame: Day 1-10
|
Day 1-10
|
Cumulative amount (Aeu ) of RAD recovered in urine over the dosing interval
Time Frame: Day 1-10
|
Day 1-10
|
Excreted Percent of RAD recovered in urine over the dosing interval
Time Frame: Day 1-10
|
Day 1-10
|
Renal Clearance (CLR ) of 50mg [14C]-SHP626
Time Frame: Day 1 -10
|
Day 1 -10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize and identify metabolites of [14C]-SHP626 in plasma by accelerator mass spectrometry for radioactivity quantification
Time Frame: Day 1 to day 10
|
Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary
|
Day 1 to day 10
|
Characterize and identify metabolites of [14C]-SHP626 in urine by accelerator mass spectrometry for radioactivity quantification
Time Frame: Day 1 to day 10
|
Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary
|
Day 1 to day 10
|
Characterize and identify metabolites of [14C]-SHP626 in feces by liquid scintillation counting
Time Frame: Day 1 to day 10
|
Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary
|
Day 1 to day 10
|
Assess the safety and tolerability of [14C]-SHP626 by adverse events (AEs) defined as changes, including changes from baseline in physical examination findings
Time Frame: Screening to day 7
|
AEs will be coded using the agreed upon version of MedDRA.
The number of events, incidence, and percentage of TEAEs will be calculated overall, by system organ class and by preferred term.
TEAEs will be further summarized by severity and relationship to investigational product.
AEs related to investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly summarized/listed.
|
Screening to day 7
|
Changes from baseline in vital signs
Time Frame: Screening to day 7
|
Screening to day 7
|
|
Changes from baseline in ECGs
Time Frame: Screening to day 7
|
Screening to day 7
|
|
Changes from baseline in hematology
Time Frame: Screening to day 7
|
Screening to day 7
|
|
Changes from baseline in coagulation
Time Frame: Screening to day 7
|
Screening to day 7
|
|
Changes in baseline in urinalysis
Time Frame: Screening to day 7
|
Screening to day 7
|
|
Changes in baseline in chemistry
Time Frame: Screening to day 7
|
Screening to day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nicholas Siebers, MD, Covance Clinical Pharmacology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
September 30, 2015
First Submitted That Met QC Criteria
October 6, 2015
First Posted (Estimate)
October 8, 2015
Study Record Updates
Last Update Posted (Actual)
May 1, 2019
Last Update Submitted That Met QC Criteria
April 30, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHP626-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Alcoholic Steatohepatitis
-
Meridian Bioscience, Inc.CompletedNon-Alcoholic SteatohepatitisUnited States, France, Belgium, United Kingdom
-
Yaqrit LtdAssistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaboratorsWithdrawnNon-Alcoholic SteatohepatitisFrance, Italy, Portugal, Spain, Switzerland, United Kingdom
-
Enanta Pharmaceuticals, IncICON Clinical Research; Triangle BiostatisticsCompletedNon-Alcoholic SteatohepatitisUnited States, United Kingdom, New Zealand, Canada, France, Puerto Rico
-
Tanta UniversityCompletedNon Alcoholic SteatohepatitisEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnNon Alcoholic SteatohepatitisIndia
-
Tanta UniversityRecruitingNon Alcoholic SteatohepatitisEgypt
-
Sunshine Lake Pharma Co., Ltd.CompletedNon-Alcoholic SteatohepatitisChina
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingNon Alcoholic SteatohepatitisUnited States
-
GenfitTerminatedNon Alcoholic SteatohepatitisUnited States
-
Bristol-Myers SquibbCompletedNon-Alcoholic SteatohepatitisUnited States
Clinical Trials on SHP626
-
Mirum Pharmaceuticals, Inc.CompletedNon-Alcoholic SteatohepatitisUnited States
-
Mirum Pharmaceuticals, Inc.TerminatedNon-Alcoholic SteatohepatitisUnited States, United Kingdom, Canada, Puerto Rico
-
Mirum Pharmaceuticals, Inc.RecruitingPrimary Sclerosing CholangitisUnited States, United Kingdom, Israel, Germany, Canada
-
Mirum Pharmaceuticals, Inc.TerminatedIntrahepatic Cholestasis of PregnancyUnited States, United Kingdom, New Zealand
-
Mirum Pharmaceuticals, Inc.RecruitingPrimary Biliary Cholangitis | PBCUnited States, United Kingdom, Israel, Germany, Italy, France
-
Mirum Pharmaceuticals, Inc.Completed